Want to see SGMT full AI Analyst Report?
Top Page
Sagimet Biosciences, Inc. Class A
(NASDAQ:SGMT)
Select Model
Select Model
Rating:58Neutral
Price Target:
$10.50
▲(2.04% Upside)
Action:Reiterated
Date:10/01/26
Overall score reflects a strong funding/leverage position and positive clinical/regulatory and financing catalysts, partially offset by the core financial reality of no meaningful revenue, continued sizable losses, and persistent cash burn. Technicals are broadly neutral and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Low leverage and expanded capital base
Extremely low leverage gives Sagimet financial flexibility while it funds clinical development. The expanded asset base and substantial equity cushion reduce balance-sheet stress, allowing management to prioritize pipeline advancement and absorb development uncertainty without relying heavily on debt.
Negative Factors
No meaningful commercial revenue
Sagimet has not yet established commercial revenue because its programs remain in development. This leaves near-term financial performance dependent on clinical progress, regulatory outcomes, and external financing rather than recurring product sales, increasing the importance of successful launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and expanded capital base
Extremely low leverage gives Sagimet financial flexibility while it funds clinical development. The expanded asset base and substantial equity cushion reduce balance-sheet stress, allowing management to prioritize pipeline advancement and absorb development uncertainty without relying heavily on debt.
Read all positive factors
Sagimet Biosciences, Inc. Class A (SGMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$562.94M
Dividend YieldN/A
Average Volume (3M)1.24M
Price to Earnings (P/E)―
Beta (1Y)2.73
Revenue GrowthN/A
EPS Growth30.54%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.28
Shares Outstanding61,591,160
10 Day Avg. Volume1,923,635
30 Day Avg. Volume1,240,484
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.46Price Target Upside176.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the Unit...
How the Company Makes Money
Sagimet Biosciences does not have publicly known material recurring revenue from marketed products; as a clinical-stage biotechnology company, its ability to generate revenue is primarily tied to financing and partnering activities rather than pro...
Sagimet Biosciences, Inc. Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 |
| EBITDA | -49.70M | -51.04M | -45.57M | -27.88M | -30.37M | -24.44M |
| Net Income | -47.08M | -51.04M | -45.57M | -27.88M | -30.50M | -24.44M |
Balance Sheet | ||||||
| Total Assets | 263.43M | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M |
| Cash, Cash Equivalents and Short-Term Investments | 240.13M | 113.12M | 151.25M | 94.90M | 32.34M | 56.73M |
| Total Debt | 1.94M | 78.00K | 78.00K | 65.00K | 211.00K | 348.00K |
| Total Liabilities | 7.28M | 5.10M | 4.45M | 5.65M | 219.98M | 217.29M |
| Stockholders Equity | 256.15M | 111.38M | 155.81M | 91.06M | -186.95M | -158.26M |
Cash Flow | ||||||
| Free Cash Flow | -41.32M | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Operating Cash Flow | -41.32M | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Investing Cash Flow | 629.00K | 4.56M | -61.68M | 12.58M | -32.01M | 0.00 |
| Financing Cash Flow | 339.66M | 275.00K | 104.82M | 86.17M | -73.00K | 9.74M |
Sagimet Biosciences, Inc. Class A Technical Analysis
Negative
10.29
Price Trends
9.75
Negative
8.43
Positive
7.17
Positive
Market Momentum
-0.18
Positive
41.22
Neutral
29.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Negative. The current price of 10.29 is below the 20-day moving average (MA) of 10.34, above the 50-day MA of 9.75, and above the 200-day MA of 7.17, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 41.22 is Neutral, neither overbought nor oversold. The STOCH value of 29.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMT.
Sagimet Biosciences, Inc. Class A Risk Analysis
Sagimet Biosciences, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Sagimet Biosciences, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sagimet Biosciences, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $411.45M | -2.47 | -64.25% | ― | ― | -29.71% | |
58 Neutral | $562.94M | -7.14 | -31.96% | ― | ― | 30.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $339.09M | -1.27 | -128.27% | ― | ― | 41.56% | |
49 Neutral | $209.48M | -1.36 | -57.61% | ― | -94.10% | -122.58% | |
48 Neutral | $108.59M | -2.55 | -38.80% | ― | -100.00% | -392.92% | |
47 Neutral | $148.93M | -4.05 | -74.36% | ― | 35.89% | 58.70% |
* Healthcare Sector Average
SGMT
Sagimet Biosciences, Inc. Class A
9.14
1.83
25.03%
CDXS
Codexis
1.36
-1.33
-49.44%
CABA
Cabaletta Bio
2.00
-0.44
-18.03%
BDTX
Black Diamond Therapeutics
1.89
-2.03
-51.79%
AVIR
Atea Pharmaceuticals
5.13
2.22
76.29%
TRDA
Entrada Therapeutics Inc
5.38
-0.54
-9.12%
Sagimet Biosciences, Inc. Class A Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sagimet Biosciences Announces Major Equity Financing Agreement
Positive
Oct 1, 2026
On September 30, 2026, Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants to purchase up to 2,750,010 shares at $9.9...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Sagimet Reports Strong Phase 3 Acne Trial Results
Positive
Sep 30, 2026
On September 30, 2026, Sagimet Biosciences reported positive 52-week results from the Phase 3 ASC40-304 open-label extension trial of denifanstat in patients with moderate to severe acne vulgaris in China, showing further improvements in lesion co...
Business Operations and StrategyRegulatory Filings and Compliance
Sagimet Wins FDA Clearance for Phase 3 Acne Trial
Positive
Aug 13, 2026
On August 13, 2026, Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for denifanstat. The agency issued a “Study May Proceed” letter, allowing the company to...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Sagimet Highlights Q2 Results and Dermatology Focus Shift
Positive
Aug 11, 2026
Sagimet Biosciences reported its second-quarter 2026 results on August 11, 2026, highlighting a strategic shift to prioritize dermatology and advance its lead FASN inhibitor denifanstat for moderate to severe acne in the U.S. The company plans a r...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Sagimet updates acne pipeline and funding strategy
Positive
Jul 21, 2026
On July 20, 2026, Sagimet Biosciences updated an investor slide presentation outlining progress across its clinical pipeline and strategic plans. The materials highlight denifanstat’s strong Phase 3 acne data generated by partner Ascletis in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.